Loss of muscle mass is a defining feature of cachexia of chronic disease. Patients suffering from cancer, chronic heart disease, chronic ob structive pulmonary disease, sepsis, and many other conditions experience involuntary weight loss and loss of muscle mass, which contributes significantly to mortality (Morley et al., 2006; Tisdale, 2009) . A decrease in volitional food intake is often associated with cachexia but is not solely responsible for the loss of muscle mass, as nutritional supplementation fails to substantially reverse changes in body weight (Evans et al., 1985) . A common pathological feature of these disparate conditions is an in crease in circulating inflammatory cytokines. Systemic administration of cytokines results in muscle catabolism in experimental animals (Acharyya et al., 2004) . Furthermore, genetic (Llovera et al., 1998) or pharmacologic block ade (Fujita et al., 1996) of cytokine signaling attenuates experimental cachexia. Numerous studies have demonstrated that inflammatory cytokines can cause atrophic changes in cultured myotubes, and in vivo studies have demonstrated that activation of inflammatory signaling path ways are fundamental to the atrophy process (Strassmann et al., 1992; Zamir et al., 1994; Acharyya et al., 2004; Doyle et al., 2011) . How ever, the catabolic effects of inflammation in vivo have not been shown to depend exclusively on direct cytokine action on skeletal muscle.
Despite the well documented role of the brain in regulating whole body metabolism, the contribution of central nervous system (CNS) inflammation to muscle atrophy has not Skeletal muscle catabolism is a co-morbidity of many chronic diseases and is the result of systemic inflammation. Although direct inflammatory cytokine action on muscle promotes atrophy, nonmuscle sites of action for inflammatory mediators are less well described. We demonstrate that central nervous system (CNS)-delimited interleukin 1 (IL-1) signaling alone can evoke a catabolic program in muscle, rapidly inducing atrophy. This effect is dependent on hypothalamic-pituitary-adrenal (HPA) axis activation, as CNS IL-1-induced atrophy is abrogated by adrenalectomy. Furthermore, we identified a glucocorticoidresponsive gene expression pattern conserved in models of acute and chronic inflammatory muscle atrophy. In contrast with studies suggesting that the direct action of inflammatory cytokines on muscle is sufficient to induce catabolism, adrenalectomy also blocks the atrophy program in response to systemic inflammation, demonstrating that glucocorticoids are requisite for this process. Additionally, circulating levels of glucocorticoids equivalent to those produced under inflammatory conditions are sufficient to cause profound muscle wasting. Together, these data suggest that a significant component of inflammationinduced muscle catabolism occurs indirectly via a relay in the CNS.
IL1, food was removed from all cages at the time of injec tion. Central administration of IL1 led to a significant and rapid induction of MAFbx, MuRF1, and Foxo1 mRNA in gastrocnemius (Gn) muscle 4-8 h after the injection (Fig. 2 a) , demonstrating rapid activation of the catabolic program in skeletal muscle in response to central inflammation. Given the known role of PI3K/Akt signaling in the regulation of muscle mass, we examined Akt phosphorylation in muscle by West ern blot after acute i.c.v. IL1 (Fig. 2 b) . No changes were observed in the phosphorylation of Akt at any time point after i.c.v. IL1 injection. To rule out the possibility that centrally administered IL1 was leaking into the systemic circulation and having a direct impact on muscle, we examined p38 MAPK phosphorylation in muscle. Signaling via this pathway occurs downstream of the type I IL1 receptor (IL1R1) and has been implicated in the regulation of MAFbx (Li et al., 2005; Doyle et al., 2011) . No changes were observed in p38 phosphorylation at any time point after central IL1 injec tion, suggesting that centrally injected cytokine is unlikely to be directly signaling in muscle (Fig. 2 b) . We also examined circulating IL1 levels after acute central IL1 injection and found no changes at any time point examined (Table I) .
We next examined whether the catabolic molecular mechanisms that are rapidly engaged after bolus i.c.v. IL1 injection can bring about muscle atrophy with time. Rats were infused with IL1 into the lateral ventricle for 3 d via been examined. The CNS is a known target of cytokine signal ing in cachexia, where cytokines act on neural feeding circuits to mediate anorexia (Scarlett et al., 2007; Grossberg et al., 2010) . Multiple inflammatory cytokines are induced in the hypothal ami of animals treated peripherally with LPS (Ogimoto et al., 2006) or in tumorbearing animals (Ropelle et al., 2007) . When CNS IL1 receptors are pharmacologically antagonized during systemic inflammation, anorexia and alterations in peripheral protein metabolism are ameliorated (Layé et al., 2000; Lloyd et al., 2003) , suggesting that CNS inflammation plays a critical role in integrating the host response to disease.
In this paper, we present evidence that CNS inflamma tion is sufficient to induce muscle atrophy independent of substantial peripheral inflammation. Activation of the hypo thalamic-pituitary-adrenal (HPA) axis is both necessary and sufficient to explain the catabolic action of central inflamma tion. Consistent with the role of the brain as a central regu lator of metabolic homeostasis, this work implicates CNS cytokine signaling in regulating the muscle catabolism in re sponse to systemic inflammation.
RESULTS

CNS inflammation and muscle catabolism are coincident states
CNS inflammation and muscle catabolism are common features in experimental models of cachexia. Mice treated with LPS or implanted with the Lewis lung carcinoma (LLC) robustly in crease the expression of inflammatory cytokines in the hypo thalamus (Fig. 1, a and c) . LPS administration results in generalized inflammation, as indicated by the upregulation of both IL1 and TNF. In contrast, tumor growth resulted only in the upregulation of IL1. Furthermore, after systemic LPS administration, IL1 expression is strongly induced within the hypothalamic arcuate nucleus as shown by in situ hybridiza tion, demonstrating endogenous production within the CNS (Fig. 1 b) . Muscle loss in cachexia occurs as a result of a decrease in protein synthesis and a concomitant increase in protein degra dation (Baracos et al., 1995) that occurs principally via the ubiq uitin proteasome system (Mitch et al., 1994; Baracos et al., 1995; Price et al., 1996) . Musclespecific E3 ubiquitin ligases, muscle atrophy Fbox (MAFbx or atrogin1), and muscle ring finger protein 1 (MuRF1; Bodine et al., 2001a; Gomes et al., 2001 ) are induced in catabolic muscle and are regulated by the forkhead box (Foxo) family of transcription factors (Sandri et al., 2004) . Increased expression of MAFbx and MuRF1 occurs in all forms of atrophy studied . Simultaneous with cen tral inflammation, the atrophy program is activated in skeletal muscle, marked by the upregulation of MAFbx, MuRF1, and Foxo1 (Fig. 1, a and c) , which in the case of tumorbearing ani mals occurs in the context of muscle mass loss (Fig. 1 d) .
Acute and chronic central administration of IL-1 results in muscle atrophy
To determine whether inflammatory signaling in the CNS plays a role in directing muscle catabolism, mice were admin istered 10 ng IL1 or vehicle (Veh) by intracerebroventricu lar (i.c.v.) injection. To control for the anorectic effects of In situ hybridization for IL-1 mRNA in the arcuate nucleus of the hypothalamus (2.80 relative to bregma; 3V, third ventricle) 8 h after LPS administration. Veh-treated animals showed no specific signal at this exposure time. (c) Atrophy gene expression in Gn and cytokine expression in hypothalamic blocks in mice bearing LLC tumors (or sham) were measured by real-time PCR (n = 5-9/group). Values are relative to GAPDH for Gn and 18s RNA for Hypo. (d) Gn muscle weight normalized to initial body weight (BW) and muscle weight change relative to Veh in LLC tumor bearing animals (n = 5-9/group). Bar, 100 µm. Data are represented as mean ± SEM. *, P < 0.05; ***, P < 0.001 as calculated by unpaired Student's t test.
sustained decrease in food intake over the course of the 3d study. Although Vehtreated animals consumed 78.6 ± 2.2 g of food over the 3d period, IL1-treated animals only con sumed 45.29 ± 4.0 g. Similar to acute injection, chronic i.c.v. infusion of IL1 increased the expression of MAFbx, MuRF1, and Foxo1 mRNAs in muscle (Fig. 2 c) . The most pronounced differences were seen in the Gn and extensor digitorum longus (EDL), which are predominantly composed osmotic minipumps at a dose (10 ng/h) thought to mimic endogenous pathophysiologic concentrations under inflam matory conditions (PlataSalamán et al., 1996) . This dose is also far below those given peripherally to induce muscle ca tabolism or anorexia (Bodine et al., 2001a; Whitaker and Reyes, 2008) . To control for the effects of IL1 on food intake, a subset of Vehtreated animals was pair fed (PF) to the IL1-treated animals. Central IL1 treatment led to a WT mice received i.c.v. injections of IL-1. Animals were sacrificed at 2, 4, and 8 h after the injection (n = 6-9/group). Plasma IL-6, IL-1, and IGF-1 levels were measured by ELISA and corticosterone was measured by RIA. ***, P < 0.001 versus corresponding Veh-injected control as calculated by two-way ANOVA with Bonferroni's post test.
in the CNS is sufficient to induce muscle atrophy, predomi nantly in fast twitch fibers. Furthermore, IL1 is a far more potent catabolic mediator when administered centrally than when given peripherally.
Central melanocortin signaling is not necessary for IL-1-induced muscle atrophy Pharmacologic blockade of the type 4 melanocortin receptor (MC4R) prevents IL1-induced anorexia (Whitaker and Reyes, 2008) and attenuates lean mass loss in experimental cachexia (Marks et al., 2001; Wisse et al., 2001; Cheung et al., 2005) . Furthermore, the MC4R is critical to the CNS regulation of many other facets of metabolism (Nogueiras et al., 2007; PerezTilve et al., 2010) . Finally, inflammatory challenges specifically upregulate IL1 mRNA in the arcu ate nucleus, which contains the proximal neurons of the cen tral melanocortin system. Based on this, we sought to examine whether the acute food intake-independent changes in mus cle catabolism initiated by IL1 are dependent on signaling at the MC4R. WT mice and mice lacking a functional MC4R (MC4RKO) were injected i.c.v. with 10 ng IL1 and were sacrificed 8 h after injection. Surprisingly, IL1 led to a similar increase in the mRNA for MAFbx, MuRF1, and Foxo1 in the Gn of both WT and MC4RKO mice (Fig. 4 a) . To further examine the role of the central melano cortin system in regulating muscle catabolism independent from its effects on food intake, rats were injected i.c.v. with 1 nmol melanotan II (MTII), an agonist at the type 3 and 4 melanocortin receptors, and were sacrificed 6 h after injec tion. MTII failed to increase the mRNA for MAFbx, MuRF1, or Foxo1 in the Gn (Fig. 4 b) . To determine the impact of increased signaling via the MC4R in the chronic state, 1 nmol MTII was administered i.c.v. every 12 h for 36 h (four injec tions), and animals were sacrificed 2 h after the final injec tion. To control for the decreased food intake associated with MTII treatment, Vehinjected con trol animals were PF with MTIItreated animals. Chronic MTII failed to increase the mRNA for MAFbx or Foxo1 relative to PF controls but led to a small increase in MuRF1 mRNA in the Gn (Fig. 4 c) .
No changes in the expression of MAFbx, MuRF1, or Foxo1 were seen in the soleus (Fig. 4 c) . Both MTIItreated and PF animals lost weight over the course of the experiment, but there was no differ ence between groups (Fig. 4 d) . MTII treatment of fast twitch fibers. These effects were largely independent from food intake as PF animals failed to show similar changes in gene expression. In contrast, the induction of MAFbx, MuRF1, and Foxo1 in the soleus was relatively small. Central IL1 infusion also resulted in significant alterations in body composition, resulting in significant food intake-independent losses of both body weight and lean mass (Fig. 2 d) . Although significant fat mass loss occurred with IL1 treatment, these changes were paralleled by the PF group. Concurrent with the changes in body composition, significant food intakeindependent loss of Gn and EDL muscles were observed (Fig. 2 e) . To examine whether the loss of muscle mass seen with i.c.v. IL1 treatment is the result of myofibrillar atro phy, fiber crosssectional area (CSA) was measured in regions of the Gn and soleus muscle composed of fast (white Gn [WGn] ) and slow (soleus) fibers. WGn fiber CSA was signifi cantly reduced by IL1 treatment but unaltered in PF ani mals (Fig. 2, f and g ). In contrast, soleus fiber CSA was only mildly reduced ( Fig. 2 f) .
To confirm that centrally infused IL1 is not diffusing systemically and acting directly on muscle, we infused IL1 i.p. at the same dose given i.c.v (10 ng/h) for 3 d. This pe ripheral IL1 treatment did not induce MAFbx, MuRF1, or Foxo1 mRNA in the Gn, soleus, or EDL (Fig. 3 a) . Unlike i.c.v. infusion, i.p. IL1 delivered at this dose did not affect Gn, soleus, and EDL weights (Fig. 3 b) . In addition, periph eral IL1 infusion did not significantly alter body weight, lean mass, or fat mass (Fig. 3 c) and failed to alter fiber CSA in the WGn or soleus (Fig. 3, d and e). To determine whether low dose systemic IL1 infusion was causing increases in circulating IL1 levels, we measured IL1 in the plasma of these animals. Circulating IL1 levels were below the limit of detection (LOD) in all samples (LOD = 93.6 pg/ml; not de picted). Collectively, these data demonstrate that inflammation (denoted in red). The complete dataset has been deposited in the GEO Omnibus database (GEO Series accession no. GSE26766). Significantly regulated genes were grouped based on their known functions in skeletal muscle. At the 2 and 4h time points there was a pronounced regulation of genes involved in regulating the inflammatory/anti inflammatory balance. At the 4 and 8h time points, altera tions in nutrient signaling were evident, with changes in mammalian target of rapamycin (mTOR) and AMPactivated protein kinase pathway members. An oxidative stress re sponse was also observed at later time points. Genes involved in cell cycle regulation and myogenic differentiation were also did not lead to significant food intake-independent losses of fat mass, lean mass, Gn, or soleus weight (Fig. 4, d and e). These results argue that the CNS mechanism by which IL1 induces food intake-independent muscle catabolism is not dependent on signaling at the MC4R.
Central IL-1 injection induces a transcriptional program in skeletal muscle, which is analogous to that seen in other forms of atrophy Changes in the mRNA profile of skeletal muscle undergoing atrophy have been extensively characterized, revealing a con served pattern of gene expression . To gain insight into how central IL1 induces muscle catabo lism, we performed cDNA microarray analysis of mouse skeletal muscle RNA at 2, 4, and 8 h after i.c.v. IL1 injec tion. Statistical analysis with a false discovery rate of 1% yielded 494 significantly regulated genes. This list was further narrowed to 100 genes by restricting it to genes that were at least 1.75 fold up or downregulated at any of the three time points (Fig. 5, Fig. S1 , and Table S2 ). The expression pattern of 10% of these genes was confirmed by realtime PCR . Food was removed from the cages at the time of injection, and animals were sacrificed at 2, 4, and 8 h after the injection (n = 3-5/group). Skeletal muscle RNA was hybridized to Affymetrix Exon 1.0 ST arrays. Data were analyzed for a false discovery rate of 0.01. Genes that were >1.75-fold up-or down-regulated at any time point were categorized based on their annotated and published functions. Heat map values are log 2 normalized array intensities. Genes with differential expression confirmed by real-time PCR are indicated in red (Fig. S1 ). § indicates genes that are annotated as glucocorticoid responsive or are regulated in muscle by glucocorticoids in published array datasets.
HPA axis. Given the significant glucocorticoidregulated gene expression signature seen in response to central inflammation, we measured serum corticosterone (the predominant circulat ing glucocorticoid in rodents) by radioimmunoassay. Similar to IL6, serum corticosterone levels were highest at 2 h after acute i.c.v. IL1, reaching 397 ± 30 versus 104 ± 16 ng/ml in Vehtreated animals, and had returned to baseline by 8 h after injection (Table I ). In contrast with plasma IL6 levels, chronic i.c.v. infusion of IL1 led to a sustained increase in circulating corticosterone at the time of sacrifice relative to Vehtreated animals, (183 ± 40 ng/ml for IL1-infused animals vs. 37 ± 21 ng/ml for Vehtreated animals; Table II ).
Activation of the HPA axis is necessary for the muscle catabolic effects of i.c.v. IL-1
To explore the involvement of HPA axis activation in i.c.v. IL1-induced muscle catabolism, mice received acute i.c.v. injections of 10 ng IL1 and were treated with the gluco corticoid/progesterone antagonist mifepristone. Mifepristone treatment attenuated the induction of MAFbx, MuRF1, and Foxo1 mRNA by i.c.v. IL1 (Fig. 6 a and Table S1 ). To confirm these findings, we used adrenalectomized (ADX) mice with low physiological corticosterone replacement. This allowed us to examine whether tonic glucocorticoids are a permissive factor in muscle catabolism or whether an increase in circulating corticosterone is the driver of atrophy. In ADX animals, i.c.v. IL1 failed to induce MAFbx to the same degree as seen in shamoperated animals, and the in duction of MuRF1 and Foxo1 by i.c.v. IL1 injection was completely blocked (Fig. 6 b and Table S1 ). In addition, the induction of the catabolic transcription factor Krüpplelike factor 15 (KLF15), which transactivates MAFbx and MuRF1 (Shimizu et al., 2011) , was blocked by ADX. These data demonstrate that an increase in circulating glucocorticoids is necessary for the acute activation of the atrophy program in response to i.c.v. IL1.
To determine if intact adrenals are necessary for food intakeindependent myofibrillar atrophy, we infused IL1 or Veh i.c.v. for 3 d in ADX corticosteronereplaced rats. To control for the effects of food intake, Vehtreated animals were PF to IL1-treated animals. No significant differences were observed in the expression of MAFbx, MuRF1, or Foxo1 in the Gn, soleus, or EDL (Fig. 6 c) . There were statis tically nonsignificant trends toward an increase in the levels significantly affected, suggesting alterations in muscle regen eration. Comparison of this dataset with two separate gene expression array studies evaluating muscle gene expression in response to glucocorticoid administration revealed multiple glucocorticoidresponsive genes (Fig. 5 , marked by §; Almon et al., 2007; Wu et al., 2010) . These data implicate HPA axis activation in mediating the changes in gene expres sion in skeletal muscle after central IL1 treatment.
Regulation of circulating growth factors and cytokines after i.c.v. IL-1
Plasma levels of IL6 were examined by ELISA after acute i.c.v. IL1 injection, as circulating IL6 increases after central IL1 administration (De Simoni et al., 1990) , and IL6 has been implicated in mediating muscle catabolism (Fujita et al., 1996) . A small induction of circulating IL6 was observed at early time points, with a peak of 298 ± 35 pg/ml at 2 h versus 13 ± 3 pg/ml in Vehtreated animals, with levels returning to baseline by 8 h (Table I) . Despite a marked increase, these levels of IL6 are quite low in comparison with those found in ani mals undergoing systemic inflammatory challenge, where peak serum values approach 7,000 pg/ml (Hansen et al., 2000) . To examine whether significant IL6 production or signaling was occurring in muscle after central IL1 treatment, we mea sured the expression of IL6 and its downstream feedback in hibitor suppressor of cytokine signaling 3 (SOCS3). We found no changes in either IL6 or SOCS3 gene expression in muscle at any time point after central injection of IL1, suggesting that significant IL6 signaling does not occur in muscle after i.c.v. IL1 injection (unpublished data). Additionally, sus tained delivery of IL1 into the CNS did not lead to an in crease in circulating IL6 levels at the end of 3 d of i.c.v. infusion (Table II) , suggesting that the elevation of IL6 after acute central IL1 treatment is a transient phenomenon.
Circulating insulinlike growth factor 1 (IGF1) contributes to the regulation of the anabolic/catabolic balance in skeletal muscle (Stitt et al., 2004) . No differences in IGF1 were observed between Veh and IL1-treated animals at any time point, with all values falling in the expected normal range (Table I) . IGF1 levels were also measured in animals infused i.c.v. with IL1 for 3 d. Serum IGF1 levels were unaffected by chronic IL1 administration relative to ad lib-fed controls (Table II) .
Glucocorticoids are known mediators of muscle catabo lism (Bodine et al., 2001a) , and inflammation activates the were observed in the weights of Gn, soleus, or EDL muscles (Fig. 6 e) . Muscle fiber CSA was also not significantly de creased by IL1 infusion relative to PF controls in either the WGn or soleus (Fig. 6, f and g ). Centrally infused IL1 was not leaking systemically, as the majority (19/20) of animals had plasma IL1 levels below the LOD (LOD = 93.6 pg/ml; not depicted).
Central IL-1 induces a glucocorticoid-dependent transcriptional program that is common to models of acute and chronic systemic inflammation To study the extent to which the transcriptional program ini tiated by central IL1 is dependent on glucocorticoid signal ing, we selected several genes identified by the array analysis to examine in ADX mice. The adipokine lipocalin2 (Lcn2) and the steroid hormone responsive transcript decidual pro tein regulated by progesterone (Depp) were highly induced by central IL1 administration, a response only slightly attenu ated by adrenalectomy (Fig. 7 a and Table S1 ). In contrast, the induction of the oxidative stress response genes metallothio nein2 (Mt2) and uncoupling protein3 (Ucp3) was com pletely blocked by ADX. The upregulation of mTOR of MAFbx and MuRF1 mRNA in the Gn (MAFbx mRNA, P = 0.09; MuRF1 mRNA, P = 0.12) and EDL (MAFbx mRNA, P = 0.19; MuRF1 mRNA, P = 0.34). Central IL1 infusion failed to generate a significant decrease in body weight, fat mass, or lean mass beyond that seen in PF animals ( Fig. 6 d) , although a statistically nonsignificant trend was seen toward the loss of lean mass (P = 0.13). No differences Bars, 100 µm. Data are represented as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by two-way ANOVA with Bonferroni's corrected t test (a and b; raw data in Table S1 ) or by unpaired Student's t test (d-g), with no comparisons reaching P < 0.05. Data represented as mean ± SEM. The dotted line in a represents Vehtreated controls at a relative quantity of 1. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by unpaired Student's t test (b and c) or two-way ANOVA with Bonferroni's corrected t test (a; raw data in Table S1 ).
Despite the lowgrade peripheral in flammation in tumorbearing animals, many of the genes examined (five of nine) were regulated in skeletal mus cle. Importantly, the glucocorticoid dependent mTOR regulators Sesn1 and REDD1 were upregulated in the muscle of tumorbearing animals, demonstrating that glucocorticoid signaling may contribute to the pathogenesis of cancer cachexia.
HPA axis activation is necessary and sufficient for muscle wasting driven by central and peripheral inflammation
To examine the role of HPA axis activation in peripheral inflammationinduced activation of the atrophy program, 250 µg/kg LPS was administered to ADX mice. The LPS mediated induction of MAFbx was attenuated in ADX mice, and the induction of MuRF1 and Foxo1 were completely prevented in ADX animals (Fig. 8 a) . The induction of KLF15, REDD1, and Sestrin-1 by LPS was also completely blocked in ADX mice. Collectively, this demonstrates that peripheral inflammationmediated activation of the atrophy program requires intact adrenal glands. Although highdose administration of synthetic gluco corticoids induces substantial atrophy, it remains unknown whether the lower levels of circulating corticosterone evoked by inflammation are sufficient to induce atrophy. To examine this possibility, rats were implanted with sustained release cort pellets at a dose known to produce circulating concentrations approximating levels seen in inflamed animals (Hansen et al., 2000; Kovács et al., 2000) . Rats were implanted with 100 or 2 × 100 mg (200 mg) corticosterone tablets, achieving mean circulating levels of 321.8 ± 43.0 and 908.5 ± 223.7 ng/ml, pathway members Sestrin-1 (Sesn1) and regulated in develop ment and DNA damage responses (REDD1 or Ddit4), as well as the downstream target Foxo3, was also inhibited by ADX. The antimyogenic basic helixloophelix transcription factor inhibitor of DNA binding 3 (Id3) was also induced by central IL1 treatment in a glucocorticoiddependent manner. The cytoskeletal protein kyphoscoliosis peptidase (KY) is dramati cally downregulated by central inflammation an effect par tially blocked by ADX. We also examined myostatin gene expression in skeletal muscle, given its known critical role in the regulation of muscle mass (Zhou et al., 2010; Zhang et al., 2011) . Myostatin was modestly induced by central IL1 ad ministration and this induction was completely blocked by adrenalectomy (Fig. 6 a) . Collectively, these genes show a pattern of regulation that is largely dependent on an intact HPA axis, although some features are independently regu lated. To confirm this expression pattern in a model of systemic inflammation, we examined the expression of these genes in LPS and tumorassociated muscle catabolism (Fig. 7,  b and c ). An identical pattern of regulation was observed in LPStreated animals, suggesting a significant glucocorticoid effect on skeletal muscle in response to peripheral inflammation. Veh-treated controls at a relative quantity of 1. Bars, 100 µm. Data represented as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001 calculated by one-way (b-f) or two-way (a) ANOVA with Bonferroni's corrected t test (raw data in Table S1 ).
central IL1 signaling attenuates many of the behavioral (Layé et al., 2000) and metabolic (Gourine et al., 1998; Lloyd et al., 2003) features of inflammatory disease. Our data show that central inflammation initiates significant muscle atrophy. Although we have demonstrated that central Il1 is sufficient for this effect, it is unlikely to be the only mediator during systemic inflammation, as many cytokines activate the HPA axis (Akita et al., 1995; Bethin et al., 2000) . We demonstrate specific production of IL1 within the arcuate nucleus under inflammatory conditions. The arcuate also contains two neu ronal groups that are known to express the IL1R1: POMC (Scarlett et al., 2007) and AgRP (Scarlett et al., 2008) neurons. The net effect of IL1 on these two neuronal groups is to increase signaling at the MC4R, decreasing food intake. In accordance with this, the anorexia associated with IL1 ad ministration is completely prevented by blockade of the MC4R (Whitaker and Reyes, 2008) . Furthermore, the loss of lean mass associated with cancer cachexia and LPS administra tion is prevented by blockade of the MC4R (Marks et al., 2001; Wisse et al., 2001) . Surprisingly, we found that signal ing at the MC4R is not necessary for central IL1-induced muscle catabolism, and MC4R activation is not sufficient to produce significant muscle catabolism. These results are in disagreement with previous work showing a protective effect of melanocortin blockade on body weight and lean mass in experimental cachexia. However, these prior studies did not separate the powerful effects of melanocortin blockade on food intake from its effects on body composition. Given the minor regulation of MuRF1 by the central melanocortin sys tem, and the effects of the melanocortin system on food in take, it is possible that the protective effects of melanocortin blockade in experimental cachexia are the result of the com bination of these two factors alone.
The precise neuroanatomic substrate via which IL1 exerts its catabolic effect remains unknown. However, given that the major downstream mediator of central inflammation induced muscle catabolism is activation of the HPA axis, there is significant evidence to implicate endothelial IL1R1 as a crucial mediator of this effect. Activation of corticotropin releasing hormone neurons in the paraventricular nucleus (the hypothalamic component of the HPA axis) by central or peripheral IL1 is blocked by knockdown of endothe lial IL1R1 (Ching et al., 2007) . Furthermore, a compo nent of this effect is mediated via endotheliumderived prostaglandin signaling in medullary catecholaminergic neurons projecting to paraventricular neurons, activating the HPA axis (Ericsson et al., 1997; Serrats et al., 2010) . Future loss offunction studies will likely examine the role of inflamma tory signaling at the level of the cerebrovascular endothelium in mediating muscle catabolism. In addition, there is a great deal of evidence that pituitary corticotrophs can be di rectly activated by inflammatory cytokines. Both leukemia inhibitory factor and IL6 can directly activate pituitary corticotrophs, leading to the release of ACTH indepen dent of hypothalamic signaling (Akita et al., 1995; Bethin et al., 2000) . respectively, versus undetectable levels (LOD = 25 ng/ml) in sham animals. Both treatments significantly induced MAfbx, MuRF1, and Foxo1 to largely the same degree (Fig. 8 b) . We additionally assessed the expression of the mTOR regulators REDD1, Sestrin-1, and KLF15, as well as the glucocorticoid responsive antiinflammatory mediator IB (Scheinman et al., 1995) , in Gn after corticosterone treatment. All four genes were significantly elevated by 100 and 200 mg corticosterone treatment (Fig. 8 b) . Significant weight loss was observed in the Gn and EDL muscle with relative sparing of the soleus (Fig. 8 c) . Both 100 and 200mg treatments also resulted in a significant loss of body weight, fat mass, and lean mass (Fig. 8 d) . Significant myofibrillar atrophy was evident in the WGn from both corticosterone treatment groups but was largely absent in the soleus (Fig. 8, e and f) . In nearly all cases, little difference was seen between 100 and 200mg treat ments, demonstrating that the atrophy program is maximally activated by corticosterone levels within the physiological range evoked by inflammation.
DISCUSSION
The CNS serves as a central regulator of whole body energy balance coordinating metabolic homeostasis in multiple pe ripheral tissues (Minokoshi et al., 2002; Nogueiras et al., 2007; Shiuchi et al., 2009) . Under normal physiological con ditions, anabolism and catabolism are regulated such that en ergy needs are met. During acute infection, skeletal muscle is mobilized to provide substrates to fuel the necessary increases in immune function. However, in cases of chronic disease where inflammation persists, muscle protein is excessively mobilized, leading to profound muscle atrophy. The regula tion of protein mobilization by inflammation occurs at nu merous levels. The direct action of inflammatory signaling molecules on skeletal muscle has been extensively examined, as has the contribution of IGF1 signaling (Bodine et al., 2001b; Rommel et al., 2001; Acharyya et al., 2004; Stitt et al., 2004; Li et al., 2005 Li et al., , 2009 Doyle et al., 2011) . The data we present in this paper demonstrate that CNS integra tion of inflammatory signaling also plays a critical role in reg ulating the anabolic/catabolic balance in muscle via activation of the HPA axis. Given that a multitude of inflammatory dis eases with underlying muscle catabolism are also marked by CNS inflammation, a central mechanism must now be con sidered when describing muscle atrophy.
To model endogenous production of IL1 in the CNS and its impact on skeletal muscle, we used i.c.v. injection to deliver physiologically relevant doses of this prototypical in flammatory cytokine. Central injection of IL1 is believed to mimic its production by the choroid plexus and circumven tricular organs (Konsman et al., 2000) and is therefore a model of endogenous inflammation. Hypothalamic IL1 produc tion is a conserved feature of a multitude of conditions associ ated with muscle catabolism, including cancer cachexia ( Fig. 1 ; PlataSalamán et al., 1998; Ropelle et al., 2007) , peripheral cytokine administration (Gayle et al., 1997) , and endotoxemia ( Fig. 1; Ogimoto et al., 2006) . Additionally, antagonism of likely subtherapeutic in these studies. Given the glucocorti coid responsive gene expression signature seen in the skeletal muscle of tumorbearing animals and the limitations of the aforementioned studies, the involvement of glucocorticoids in tumorassociated muscle wasting appears likely. Future ge netic lossoffunction studies will likely shed light on the con tribution of glucocorticoids to muscle wasting in cancer.
The molecular mechanisms underlying glucocorticoid induced atrophy have been extensively studied at the level of skeletal muscle and are driven to a large degree by transcrip tional changes. Our array analysis is unique in the literature in that it offers insight into these early transcriptional events that take place after endogenous activation of the HPA axis. The upregulation of catabolic machinery after central IL1 administration likely occurs via several molecular mecha nisms. Glucocorticoids directly transactivate the MuRF1 gene in synergy with Foxo1 (Waddell et al., 2008) . In addi tion, Foxo1 expression is induced by both central IL1 and lowdose glucocorticoids. Although the principle mechanism for the regulation of the activity of Foxo transcription factors with regard to their catabolic activity is via Aktdependent phosphorylation and nuclear exclusion (Sandri et al., 2004) , we saw no evidence for alterations in the IGF1-Akt signal ing pathway in response to central inflammation. However, increased levels of Foxo1 have been extensively correlated with atrophy (Jagoe et al., 2002; Lecker et al., 2004; Sacheck et al., 2007; Shimizu et al., 2011) . Furthermore, overexpres sion of Foxo1 in muscle is sufficient to produce atrophy (Kamei et al., 2004) . Myostatin is another mediator of skeletal muscle catabolism that is induced by central inflammation in an HPA axis-dependent manner. Blockade of myostatin signaling at tenuates the induction of MAFbx and MuRF1 in a variety of catabolic states (Zhou et al., 2010; Zhang et al., 2011) . KLF15 is another transcription factor that has recently been impli cated in the regulation of skeletal muscle catabolism. KLF15 is directly induced by glucocorticoids and transactivates both MAFbx and MuRF1 (Shimizu et al., 2011) . The sup pression of protein synthesis by glucocorticoids is also exe cuted via several distinct mechanisms, all converging to inhibit mTOR signaling. REDD1 is directly transactivated by the glucocorticoid receptor and inhibits mTOR activity via the tuberous sclerosis complex (Wang et al., 2006) . Sestrin-1 is another negative regulator of mTOR signaling in response to genotoxic stress via activation of the tuberous sclerosis complex and AMPK (Budanov and Karin, 2008 ). An integral role for sestrin signaling in the catabolic process has not yet been described; however, their role in metabolic signaling cascades makes them likely targets of future studies. Protein synthesis via the mTOR complex is also regulated by the transcription factor KLF15 (Shimizu et al., 2011) . The concerted upregulation of multiple inhibitors of mTOR signaling suggests that central inflammation elicits concerted decreases in protein synthesis and increases in protein break down to evoke atrophy.
We found a distinct set of genes that was regulated in skel etal muscle after IL1 treatment and was not returned to Increased levels of circulating glucocorticoid are neces sary for muscle catabolism as a result of fasting (Wing and Goldberg, 1993) , sepsis (Tiao et al., 1996) , and acute diabetes (Hu et al., 2009) , as adrenalectomy or administration of mife pristone attenuates muscle wasting in these states. Consistent with this, we found that central inflammation also requires an intact HPA axis to induce muscle catabolism. Furthermore, models of peripheral inflammationinduced musclewasting share a similar glucocorticoidresponsive gene expression sig nature, suggesting this response relies on HPA axis activation. Surprisingly, induction of the atrophy program by LPS was almost entirely blocked by adrenalectomy. LPS has been pro posed to induce muscle catabolism via direct action on muscle, or via the production of cytokine intermediates such as TNF or IL1, which act directly on muscle (Li et al., 2005 (Li et al., , 2009 Doyle et al., 2011) . Our data suggest that HPA axis activation is an integral part of the catabolic response to inflammation and that glucocorticoids may synergize with cyto kines acting directly on muscle to promote atrophy. Inter estingly, musclespecific loss of function of the cytokine receptor adaptor protein TRAF6 ameliorated tumorinduced muscle atrophy, implicating cytokine action on the myocyte as a mediator of atrophy (Paul et al., 2010) . However, atrophy as a result of denervation is also attenuated in musclespecific TRAF6 knockout mice. Given that denervation atrophy is not believed to occur via systemic inflammation, this finding suggests that TRAF6 may play some as yet unspecified role in muscle atrophy independent of its role in transducing inflam matory cytokine signals. Indeed, the inflammatory signaling apparatus has been generally implicated in mediating the atro phic response in skeletal muscle. NFB activity is increased in the muscle of tumorbearing mice, and dominant negative inhibition of NFB signaling blocks tumorassociated muscle atrophy (Cai et al., 2004) . NFB also plays a critical role in the atrophy process in response to denervation and unloading, both of which are not thought to rely on systemic inflamma tion (Hunter and Kandarian, 2004; Mourkioti et al., 2006) . Therefore, it is likely that signaling via TRAF6 and NFB plays a fundamental role in atrophy beyond their role in the transduction of systemic inflammatory signals.
Despite the fact that elevated glucocorticoid levels are found in models of cancer cachexia (Rivadeneira et al., 1999) , it is widely accepted that they do not participate in muscle atrophy associated with tumor growth (Tessitore et al., 1994; Llovera et al., 1996) . However, it is difficult to rule out a role for endogenous glucocorticoids on the basis of these studies. Two of these studies used the same tumor model (YAH130), which grows in the peritoneal cavity and likely directly im pacts organ function. Furthermore, food intake was not re moved as a variable in these studies. Despite this, a trend toward improvement was observed in ADX tumorbearing animals with regard to skeletal muscle protein content (Tessitore et al., 1994) . Pharmacologic blockade of glucocorticoid re ceptors with mifepristone has been unsuccessful in cancer ca chexia; however, given the 1-2h halflife of this drug in rodents (Heikinheimo et al., 1994) , the once daily dosing was by the indicated group. Rats were sacrificed by decapitation under isoflurane anesthesia, and mice were sacrificed by decapitation under anesthesia from a ketamine cocktail. Experiments were conducted in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Animal Care and Use Committee of Oregon Health & Science University.
Real-time PCR
Total muscle RNA was extracted using the RNeasy fibrous tissue mini kit (QIAGEN) and hypothalamic RNA was extracted using an RNeasy mini kit according to the manufacturer's instructions. cDNA was tran scribed using TaqMan reverse transcription reagents and random hexamers according to the manufacturer's instructions. PCR reactions were run on an ABI 7300 (Applied Biosystems), using TaqMan universal PCR master mix with the following TaqMan gene expression assays: mouse GAPDH (Mm99999915_g1), mouse MAFbx (Mm00499518_m1), mouse MuRF1 (Mm01185221_m1), mouse Foxo1 (Mm00490672_m1), mouse Lcn2 (Mm01324470_m1), mouse Mt2 (Mm00809556_s1), mouse Sesn1 (Mm01185732_m1), mouse DEPP (Mm04206895_m1), mouse UCP3 (Mm00494077_m1), mouse FOXO3 (Mm01185722_m1), mouse Selp (Mm00441295_m1), mouse Nfkbia (Mm00477798_m1), mouse Id3 (Mm00492575_m1), mouse Ky (Mm00600373_m1), mouse REDD1 (Mm00512504_g1), mouse KLF15 (Mm00517792_m1), rat GAPDH (Rn99999916_s1), rat MAFbx (Rn00591730_m1), rat MuRF1 (Rn00590197_ m1), rat Foxo1 (Rn01494868_m1), rat IL1 (Rn00580432_m1), rat KLF15 (Rn00585508_m1), rat REDD1 (Rn01433735_g1), rat Sesn1 (Rn01440906_m1), and rat Nfkbia (Rn01473657_g1; Applied Biosystems). Relative expression was calculated using the Ct method and was nor malized to Vehtreated control. Statistical analysis was performed on the normally distributed Ct values. For analyses involving two variables, raw data and twoway ANOVA results can be found in Table S1 .
Microarray analysis
Gene expression microarrays were performed in the Department of Oncol ogy at the University of Alberta, Canada.
Synthesis of cRNA and cDNA, labeling, and hybridization of arrays. Protocols and temperature cycling conditions for cDNA synthesis and in vitro transcription of cRNA, hydrolysis of cRNA (by RNase H) and fragmentation (by APE 1), as well as labeling of singlestranded cDNA, were as described by the manufacturers (Ambion and Applied Biosystems) and the WT Expression kit (Ambion). The reaction mix contained 500 ng of total RNA. The reaction mix was spiked with PolyA RNA (Product Number 900433) to monitor the amplification and labeling process independent of the quality of the initial total RNA used in the reactions. Reaction products at each of the synthesis steps were quantified using the NanoDrop 1000 spectrophotometer. Samples were biotinylated using the WT Terminal Labeling kit (Affymetrix) adhering to the experimental protocols described by the supplier. Samples were hybridized using the Gene Chip Hybridization Control kit (Affymetrix) and the GeneChip Hybridization, Wash, and Stain kit (Affymetrix). Arrays were scanned using the GeneChiP Scanner 3000 7G (Affymetrix).
Gene expression arrays. The total RNA was quantified using a Nano Drop 1000 Spectrophotometer (NanoDrop Technologies) and its integrity evaluated using a Bioanalyzer 2100 (Agilent Technologies) according to the manufacturer's protocols. RNA samples with RNA integrity numbers >5.0 were used in this study (mean of 28 samples is 6.68; maximum value at 8.3 and minimum at 5.1). Mouse expression array (GeneChip Mouse Exon 1.0 ST Array; Affymetrix) were used to capture gene expression profiles in the sam ple sets. These arrays are designed to capture all exons, each with multiple probes per exon, and are amenable to analysis both for alternatively spliced transcripts (all exons individually) and genelevel expression from multiple probes from exons to yield a single expression level data point reflecting transcripts derived from a single gene. For the current analysis, we used genelevel expression analysis (core analysis) and deferred the exon/splice baseline by adrenalectomy. Although a causative role cannot be ascribed to any of these genes in central IL1-induced muscle catabolism, this pattern does demonstrate a glucocorticoid independent effect of i.c.v. IL1 on skeletal muscle. Recent work has shown that two discrete events are necessary for muscle catabolism in acute diabetes, where both a loss of skel etal muscle insulin signaling and pathophysiologic levels of glucocorticoid are required (Hu et al., 2009 ). Critical to the interpretation of these studies is the distinction between phys iological levels and pharmacologic dosing of glucocorticoids. It is well known that administration of the synthetic glucocor ticoid dexamethasone, in doses far exceeding the physiologi cal range, is sufficient to induce muscle atrophy (Bodine et al., 2001a) . However, when dexamethasone is given at a dose es timated to mimic endogenous activation of the HPA axis, no muscle atrophy is observed (Hu et al., 2009) . In contrast, we demonstrated that administration of the endogenous gluco corticoid corticosterone, at a dose that mimics the inflamma tory activation of the HPA axis, produces dramatic muscle atrophy. This discrepancy is likely a result of the differences between dexamethasone and corticosterone including po tency, metabolism, and activity at the mineralocorticoid re ceptor. Regardless, the levels of circulating corticosterone we achieved in this study are well within the physiological range and comparable with those seen in a multitude of diseases as sociated with muscle wasting (Tanaka et al., 1990; Llovera et al., 1996) . Therefore, it is likely that glucocorticoids are necessary and sufficient to explain a significant portion of muscle catab olism in many forms of chronic disease. However, the incom plete blockade of atrophy gene induction by ADX during both central and systemic inflammation demonstrates that other mechanisms play critical roles in regulating catabolism in response to inflammation.
The finding that CNS inflammation elicits muscle atro phy illustrates a new anatomical target for cytokineinduced muscle catabolism. This study is the first to demonstrate that inflammatory cytokines cause muscle breakdown by acting within the brain. In addition to the direct effects of inflam matory cytokines on skeletal muscle, the action of cytokines in the CNS to influence skeletal muscle metabolism must now be considered. The upregulation of inflammatory cyto kines in the CNS in disease models of cachexia is well docu mented, indicating that this pathway is generally activated in diseases associated with muscle wasting. Further studies will likely examine the general contribution of the CNSmediated muscle wasting in cachexia and may discover new therapeutic targets for muscle wasting diseases.
MATERIALS AND METHODS Animals
20-25g WT C57BL/6J mice were obtained from The Jackson Laboratory. 250-350g Sprague Dawley were purchased from Charles River. MC4RKO mice were as used as previously reported (Huszar et al., 1997) . MC4RKO mice were backcrossed at least 10 generations into the C57BL/6J strain. All animals were maintained on a normal 12:12h light/dark cycle and provided ad libitum access to water and food (rodent diet 5001; Purina Mills), except in the case of PF animals in which food intake was restricted to that consumed (model 2001; Alzet) . Cannulas were implanted into the lateral ventricle under isoflurane anesthesia, using a stereotactic alignment instrument (Kopf) at the following coordinates relative to bregma: 1.5 mm X, 1.0 mm Y, and 4.0 mm Z. Mini osmotic pumps delivering 10 ng rat IL1 per hour (R&D Systems) were connected via polyethylene catheters to the cannulas and implanted subcutaneously. Body composition analysis was performed 2 d before surgery, and again immediately before sacrifice, using an EchoMRI 4in1 NMR system (EchoMRI).
Peripheral infusions
Mini osmotic pumps (model 1003D; Alzet) delivering 10 ng rat IL1 per hour were implanted into the peritoneal cavity of Sprague Dawley rats under isoflurane anesthesia. Body composition analysis was performed as per chronic i.c.v. infusion.
LPS treatment
Mice were injected with 250 µg/kg LPS (SigmaAldrich) dissolved in nor mal saline/0.5% BSA and sacrificed 8 h later. For studies examining hypo thalamic gene expression, animals were perfused with DEPCtreated PBS before the dissection of hypothalamic blocks to remove circulating immune cells from the tissue.
Adrenalectomy
ADX animals were purchased from Charles River. Animals were implanted with 21d sustained release corticosterone tablets (Innovative Research of America) immediately after arrival.
Corticosterone pellet implantation
For corticosterone replacement in ADX animal, rats were implanted with 35mg tablets and mice were implanted subcutaneously with 1.5mg tablets, both of which are known to produce low physiological levels of corticosterone (Kovács et al., 2000; Pruett and Padgett, 2004) . Animals were maintained with 0.9% saline drinking water and allowed to recover at least 1 wk before cannula implantation. To achieve stressed levels of circulating corticosterone, Sprague Dawley rats were implanted with 100 or 2× 100mg corticosterone tablets which are known to produce circulating levels approximating those seen in stressed animals (Kovács et al., 2000) .
Western blotting
Muscles were homogenized in RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X100, 0.25% Na deoxycholate, and 1 mM NaF) and supplemented with Complete protease inhibitors and PhosSTOP phosphatase inhibitor (Roche) for 5 min using a Polytron homogenizer (Kine matica). Samples were incubated on ice for 1 h, and centrifuged at 13,000 RPM for 10 min at 4°C. 50 µg of total protein per lane was run on NuPage BisTris 4-12% gradient polyacrylamide gels (Invitrogen) and transferred to Immobilon FL PVDF membranes (Millipore). Proteins were detected using the following antibodies and quantitated using an Odyssey System (LICOR Biosciences): rabbit anti-phospho AKT Ser473 D9E, mouse anti-Pan AKT 40D4, rabbit anti-phospho p38 Thr180/Tyr182 D3F9 (Cell Signaling Technology), E7 tubulin (Developmental Studies Hybridoma Bank), IRDye 800CW goat antimouse IgG, and IRDye 680LT goat anti-rabbit IgG (LICOR Biosciences).
Plasma ELISA and RIA
IL6 and IGF1 were measured by ELISA (R&D Systems) according to the manufacturer's instructions. Plasma corticosterone levels were measured by RIA (MP Biomedicals) according to the manufacturer's instructions.
In situ hybridization
Rats were injected with 250 µg/kg LPS and sacrificed 8 h after injection. 20µm coronal sections were cut on a cryostat and thawmounted onto Superfrost Plus slides (VWR Scientific). Hypothalamic sections were collected in a 1:6 series from the diagonal band of Broca (bregma, 0.50 mm) caudally through the mam millary bodies (bregma, 5.00 mm). 0.15 pmol/ml of an antisense 33 Plabeled rat IL1 riboprobe (corresponding to bases 316-762 of rat IL-1b; GenBank variant analysis for future data mining pending development of new analytical tools. The complete dataset has been deposited in the GEO Omnibus database (GEO Series accession no. GSE26766).
Data processing. The gene expression data were normalized and trans formed using GeneSpring GX 11.5. Using a Core analysis, the data were summarized using RMA16, log transformed, and baselined to the median in all samples. A oneway ANOVA was performed on the log 2 normalized in tensities. After correcting the pvalues for multiple comparisons using the BenjaminiHochberg correction at a false discovery rate of 1%, 494 probes were declared significantly expressed (P < 2.8 × 10 5 ). Only probes that showed 1.75fold up or downregulation at any of the time points were considered. Genes were organized into functional categories based on GeneRIFs (National Center for Biotechnology Information) and reported function in skeletal muscle (Table S2) .
Immunohistochemistry
Cryosections of Gn-soleus complex were cut in cross section. For laminin staining, 20µm sections were fixed for 15 min in 4% PFA and then blocked in PBS (10 mM NaPO 4 and150 mM NaCl)/10% BSA for 1 h at room tem perature. Sections were then incubated overnight at room temperature with a rabbit antilaminin antibody (SigmaAldrich) diluted 1:50 in PBS/0.1% BSA, washed with PBS/0.025% Triton X100, and incubated in a goat antirabbit Alexa Fluor 488 or 555nm labeled secondary antibody (Invitrogen) diluted 1:500 in PBS/10% BSA. Sections were mounted with Vectashield fluorescent mounting media (Vector Laboratories). For analysis of muscle fiber type, 9 µm of unfixed cryosections were blocked for 1 h in PBS/1% BSA/10% goat serum and then incubated overnight in primary antibody diluted 1:250 in PBS/1% BSA/10% goat serum. The following primary antibodies were used: SC71 for myosin IIa, BFF3 for myosin IIb (Developmental Studies Hybridoma Bank, University of Iowa, Iowa City, IA), and anti-Myosin I (Vector Laboratories). Sections were washed in PBS/0.025% Triton X100 and incubated with a goat anti-mouse Alexa Fluor 488 nm-labeled secondary antibody (Invitrogen) diluted 1:500 in PBS/10% BSA. Sections were mounted with Vectashield fluorescent mounting media. Fiber area was measured in images that were acquired on a (DM4000 B microscope; Leica), using a cam era (DFC340 FX; Leica) at ambient temperature at 100× magnification using Applications software (Suit 3.6; Leica). Images were segmented in ImageJ (National Institutes of Health) using a coherence enhanced diffusion filter. Images were pseudocolored using ImageJ. Images demonstrating fiber type distribution were obtained using a FW1000 confocal microscope at 100× using FluoView software (Olympus).
LLC tumor implantation
C57BL/6J mice were injected with (1 × 10 7 cells per site) Tumors were allowed to grow for 21 d and animals were sacrificed. Tumor weight at sacri fice averaged 2.4 ± 0.4 g. Gn muscle and hypothalamic blocks were stored in RNAlater (Ambion) according to the manufacturer's instructions.
i.c.v. injection
For 26gauge lateral ventricle cannulas (mice) and 22gauge lateral ventricle cannulas (rats; PlasticsOne) under isoflurane anesthesia, a stereotactic align ment instrument (Kopf) was used at the following coordinates relative to bregma: for mice, 1.0 mm X, 0.5 mm Y, and 2.25 mm Z; for rats, 1.5 mm X, 1.0 mm Y, and 4.0 mm Z. 10ng mouse IL1 (R&D Systems) injections were given in 1 µl total volume. IL1 was dissolved in artificial cerebrospinal fluid (aCSF; 150 mM NaCl, 3 mM KCl, 1.4 mM CaCl 2 , 0.8 mM MgCl 2 , and 1.0 mM NaPO 4 ) with 0.1% endotoxin free BSA. MTII (Phoenix Pharmaceuticals) was dissolved in aCSF and adminis tered at 1 nmol/5 µl volume. Chronic injections were performed by ad ministering MTII every 12 h for 36 h (four injections total). 10 mg/kg mifepristone (SigmaAldrich) was dissolved in sesame oil and administered 30 min before i.c.v. injection and 4 h after i.c.v. injection.
Chronic lateral ventricle infusions were performed in Sprague Dawley rats using brain infusion kits (Brain Infusion kit II) and osmotic minipumps accession no. NM_031512.2) was denatured, dissolved in hybridization buffer along with 1.7 mg/ ml tRNA, and applied to slides. Slides were covered with glass coverslips, placed in a humid chamber, and incubated overnight at 55°C. The following day, slides were treated with RNase A and washed under condi tions of increasing stringency. Slides were dipped in 100% ethanol, air dried, and then dipped in NTB2 liquid emulsion (Kodak). Slides were developed 4 d later and cover slipped.
Statistical analysis
Data are expressed as mean ± SEM. Statistical analysis was performed using Prism software (Version 4.0; Prism Software Corp.). All data were analyzed with either an unpaired Student's t test, oneway ANOVA followed by a post hoc analysis using a Bonferroni's corrected t test, or a twoway ANOVA followed with post hoc analysis using a Bonferroni's corrected t test. For the measure ments of serum growth factors and hormones, some samples had undetectable levels of the analyte. For these analyses, normal distribution of the data cannot be assumed, and a KruskalWallis test was used with a Dunn's multiple compari son post test. For all analyses, significance was assigned at the level of P < 0.05. Fig. S1 shows heat map data for the remainder of the microarray data meet ing the inclusion criteria not displayed in Fig. 5 . Table S1 contains the raw dCT data from realtime PCR experiments in which twoway ANOVAs were performed and the corresponding pvalues. Table S2 contains Gen Bank accession nos., where available, and pvalues for all microarray probe sets meeting the inclusion criteria. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20111020/DC1.
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